Moderna Receives FDA Approval for Updated COVID-19 Vaccine Targeting the KP.2 Variant of SARS-CoV-2 Page 1

The 2024-2025 Spikevax formula is expected to be available in pharmacies and healthcare facilities in the U.S. in the days immediately following approval.

CAMBRIDGE, MA / ACCESSWIRE / August 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Spikevax (formula 2024-2025) for individuals 12 years of age and older. Emergency Use Authorization (EUA) for Moderna’s COVID-19 Vaccine (formula 2024-2025) has also been granted for individuals 6 months through 11 years of age. Moderna’s updated COVID-19 vaccine targets the KP.2 variant of SARS-CoV-2 to help prevent COVID-19 in individuals 6 months of age and older. With the U.S. FDA’s decision, Moderna’s updated vaccine is expected to be available in the coming days.